<DOC>
	<DOCNO>NCT00577421</DOCNO>
	<brief_summary>A 2-year , Multicenter , Open-label , Phase IIIb Extension Study Assess Bone Mineral Density Bone Turnover Response 5 mg Daily Risedronate Treatment Women Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093 , RVE1996077 , RVE1998080 , RVE2001079 ( NCT01249261 )</brief_summary>
	<brief_title>Study Assess BMD Bone Turnover Response 5 mg Daily Risedronate Treatment Women With PMO</brief_title>
	<detailed_description>A 2-year , Multicenter , Open-label , Phase IIIb Extension Study Assess Bone Mineral Density Bone Turnover Response 5 mg Daily Risedronate Treatment Women Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093 , RVE1996077 , RVE1998080 , RVE2001079 ( NCT01249261 )</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>satisfactorily complete Clinical Study RVE2001079 ( Year 8 extension study ) Can use bone modify substance except risedronate</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>